Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxford’s COVID-19 Vaccine Makers To Parallel Clinical Studies

Merck KGaA, Halix NV, And Others Combine Expertise

Executive Summary

An industry consortium will drive forward new manufacturing processes in parallel with the Oxford group’s COVID-19 vaccine clinical studies; these studies could produce Phase III efficacy results by this autumn.

You may also be interested in...



India's Serum Joins Oxford Efforts To Expedite COVID-19 Vaccine

After partnering with Merck KGaA and Cobra Biologics, Oxford University has now tied up with Serum Institute of India to manufacture its COVID-19 vaccine and a marketing pact is likely. With clinical trials of the ChAdOx1 nCoV-19 vaccine underway, Serum intends to set aside other COVID-19 vaccine development plans for the time being.

Coronavirus Update: Moderna Scales Up Manufacturing, Sosei Looks To Structure-Based Design, Taking Stock Of India’s Lockdown

Moderna details plans on how it will make enough of its coronavirus vaccine, and Sosei is using structure-based design technology to target a SARS-CoV-2 non-strucural protein. Meanwhile, the industry in India faces up to lockdown. 

Coronavirus Update: UK Calls For COVID-19 Patients To Join Trials

GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel